Disease Domain | Count |
---|---|
Neoplasms | 7 |
Endocrinology and Metabolic Disease | 2 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 4 |
Recombinant protein | 1 |
Small molecule drug | 1 |
Monoclonal antibody | 1 |
Recombinant polypeptide | 1 |
Target |
Mechanism HER2 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FGF21R agonists |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ENG inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date05 Nov 2021 |
Sponsor / Collaborator |
Start Date26 Oct 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ARX-517 ( PSMA x Tubulin ) | Metastatic castration-resistant prostate cancer More | Phase 2 Clinical |
Pegbelfermin(Ambrx, Inc.) ( FGF21R ) | Diabetes Mellitus, Type 2 More | Phase 2 |
Long acting relaxin ( SARS-CoV-2 S protein ) | Heart Failure More | Phase 1 |
ARX-305 ( CD70 ) | Hematologic Neoplasms More | IND Application |
TLR 7/8 agonist(Ambrx) ( TLR7 x TLR8 ) | Neoplasms More | Preclinical |